• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.可溶性程序性死亡配体1作为弥漫性大B细胞淋巴瘤患者总生存期的预后生物标志物：一项508例患者的重复研究及联合分析
Leukemia. 2017 Apr;31(4):988-991. doi: 10.1038/leu.2016.385. Epub 2017 Jan 27.
2
Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.原发性中枢神经系统弥漫性大 B 细胞淋巴瘤的肿瘤微环境和免疫检查点特征。
Virchows Arch. 2020 Jun;476(6):891-902. doi: 10.1007/s00428-019-02695-6. Epub 2019 Dec 6.
3
Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.弥漫性大 B 细胞淋巴瘤肿瘤微环境中程序性细胞死亡蛋白 1 和程序性细胞死亡配体 1 表达的临床病理分析。
Histopathology. 2016 Jun;68(7):1079-89. doi: 10.1111/his.12882. Epub 2015 Dec 1.
4
Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.原发性皮肤弥漫性大B细胞淋巴瘤中的肿瘤微环境与检查点分子——新的治疗靶点
Am J Surg Pathol. 2017 Jul;41(7):998-1004. doi: 10.1097/PAS.0000000000000851.
5
Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis.弥漫性大 B 细胞淋巴瘤中的肿瘤微环境：作用与预后。
Anal Cell Pathol (Amst). 2019 Dec 16;2019:8586354. doi: 10.1155/2019/8586354. eCollection 2019.
6
Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.程序性细胞死亡蛋白1/程序性细胞死亡配体1在原发性胃肠道弥漫性大B细胞淋巴瘤肿瘤微环境中的表达
Pathol Res Pract. 2018 Apr;214(4):507-512. doi: 10.1016/j.prp.2018.03.001. Epub 2018 Mar 12.
7
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.程序性细胞死亡配体1的表达与弥漫性大B细胞淋巴瘤患者的总生存期较差相关。
Blood. 2015 Nov 5;126(19):2193-201. doi: 10.1182/blood-2015-02-629600. Epub 2015 Aug 3.
8
Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.程序性细胞死亡配体1（PD-L1）在弥漫性大B细胞淋巴瘤中的表达及临床价值：一项回顾性研究
Chin J Cancer. 2017 Dec 16;36(1):94. doi: 10.1186/s40880-017-0262-z.
9
PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.EBV 阴性弥漫性大 B 细胞淋巴瘤中 PD-L1 的表达：临床病理特征及预后意义
Oncotarget. 2016 Sep 13;7(37):59976-59986. doi: 10.18632/oncotarget.11045.
10
Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.PD-1 和 TIM-3 在弥漫性大 B 细胞淋巴瘤 CD3+ T 细胞上的预后价值。
Biomed Pharmacother. 2015 Oct;75:83-7. doi: 10.1016/j.biopha.2015.08.037. Epub 2015 Sep 15.

引用本文的文献

1
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.高 PDL1/PDL2 基因表达与原发性纵隔大 B 细胞淋巴瘤的不良预后相关。
Blood Adv. 2023 Dec 12;7(23):7331-7345. doi: 10.1182/bloodadvances.2023011169.
2
Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.可溶性程序性死亡配体-1（sPD-L1）在淋巴瘤中的预后价值：系统评价和荟萃分析。
Ann Hematol. 2023 Sep;102(9):2425-2434. doi: 10.1007/s00277-023-05325-z. Epub 2023 Jun 29.
3
The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers.爱泼斯坦-巴尔病毒对免疫检查点的影响：淋巴增生性疾病和癌症的证据及后果
Biomolecules. 2022 Mar 4;12(3):397. doi: 10.3390/biom12030397.
4
Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.非经典单核细胞易于迁移至弥漫性大 B 细胞淋巴瘤肿瘤中。
Front Immunol. 2021 Dec 16;12:755623. doi: 10.3389/fimmu.2021.755623. eCollection 2021.
5
The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis.循环可溶性程序性死亡配体-1在癌症中的预后价值：一项荟萃分析
Front Oncol. 2021 Feb 25;10:626932. doi: 10.3389/fonc.2020.626932. eCollection 2020.
6
Circulating Myeloid Regulatory Cells: Promising Biomarkers in B-Cell Lymphomas.循环髓系调节细胞：B 细胞淋巴瘤有前途的生物标志物。
Front Immunol. 2021 Feb 2;11:623993. doi: 10.3389/fimmu.2020.623993. eCollection 2020.
7
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma.可溶性程序性死亡受体1（PD-1）而非程序性死亡配体1（PD-L1）水平可预测高危弥漫性大B细胞淋巴瘤患者的不良预后。
Cancers (Basel). 2021 Jan 22;13(3):398. doi: 10.3390/cancers13030398.
8
Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.利用免疫检查点抑制剂激活非霍奇金淋巴瘤的抗肿瘤免疫反应。
J Immunol Res. 2020 Nov 18;2020:8820377. doi: 10.1155/2020/8820377. eCollection 2020.
9
Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer.干扰素-γ诱导胃癌中程序性死亡受体配体1（PD-L1）的表达及可溶性PD-L1的产生。
Oncol Lett. 2020 Sep;20(3):2161-2168. doi: 10.3892/ol.2020.11757. Epub 2020 Jun 19.
10
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.原发性中枢神经系统弥漫性大 B 细胞淋巴瘤患者血清可溶性程序性死亡配体 1（sPD-L1）水平。
BMC Cancer. 2020 Feb 13;20(1):120. doi: 10.1186/s12885-020-6612-2.

本文引用的文献

1
T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.弥漫性大 B 细胞淋巴瘤中的 T 细胞缺陷涉及髓系来源的抑制细胞的扩增。
Blood. 2016 Aug 25;128(8):1081-92. doi: 10.1182/blood-2015-08-662783. Epub 2016 Jun 23.
2
Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.弥漫性大 B 细胞淋巴瘤肿瘤微环境中程序性细胞死亡蛋白 1 和程序性细胞死亡配体 1 表达的临床病理分析。
Histopathology. 2016 Jun;68(7):1079-89. doi: 10.1111/his.12882. Epub 2015 Dec 1.
3
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.程序性细胞死亡配体1的表达与弥漫性大B细胞淋巴瘤患者的总生存期较差相关。
Blood. 2015 Nov 5;126(19):2193-201. doi: 10.1182/blood-2015-02-629600. Epub 2015 Aug 3.
4
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.巨噬细胞对弥漫性大B细胞淋巴瘤患者的预后影响：一项来自北欧II期试验的相关性研究。
Haematologica. 2015 Feb;100(2):238-45. doi: 10.3324/haematol.2014.113472. Epub 2014 Nov 7.
5
The tumour microenvironment in B cell lymphomas.B 细胞淋巴瘤的肿瘤微环境。
Nat Rev Cancer. 2014 Aug;14(8):517-34. doi: 10.1038/nrc3774. Epub 2014 Jul 10.
6
Programmed death-1 pathway in cancer and autoimmunity.程序性细胞死亡蛋白 1 通路与癌症和自身免疫。
Clin Immunol. 2014 Jul;153(1):145-52. doi: 10.1016/j.clim.2014.04.010. Epub 2014 Apr 26.
7
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.血液中高水平的可溶性程序性细胞死亡配体 1 影响侵袭性弥漫性大 B 细胞淋巴瘤的总生存期：来自法国多中心临床试验的结果。
Leukemia. 2014 Dec;28(12):2367-75. doi: 10.1038/leu.2014.137. Epub 2014 Apr 15.
8
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.在自体造血干细胞移植治疗弥漫性大 B 细胞淋巴瘤后，采用派利珠单抗阻断程序性死亡-1 来消除免疫耐受：一项国际 II 期试验的结果。
J Clin Oncol. 2013 Nov 20;31(33):4199-206. doi: 10.1200/JCO.2012.48.3685. Epub 2013 Oct 14.
9
Oncology meets immunology: the cancer-immunity cycle.肿瘤学与免疫学：癌症免疫周期。
Immunity. 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.
10
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer.中性粒细胞与淋巴细胞比值可预测癌症患者的生存情况。
Br J Cancer. 2012 Aug 7;107(4):695-9. doi: 10.1038/bjc.2012.292. Epub 2012 Jul 24.

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.

作者信息

Rossille D, Azzaoui I, Feldman A L, Maurer M J, Labouré G, Parrens M, Pangault C, Habermann T M, Ansell S M, Link B K, Tarte K, Witzig T E, Lamy T, Slager S L, Roussel M, Milpied N, Cerhan J R, Fest T

机构信息

UMR U1236, Université de Rennes 1, INSERM, EFS, Rennes, France.

Laboratoire d'hématologie, Pôle biologie, FHU CAMIn, CHU Rennes, Rennes, France.

出版信息

Leukemia. 2017 Apr;31(4):988-991. doi: 10.1038/leu.2016.385. Epub 2017 Jan 27.

DOI:10.1038/leu.2016.385
PMID:28035137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5915627/
Abstract
摘要